Simultaneous estimation of rosuvastatin and fenofibrate by hplc

buy now

Introducing our advanced HPLC method for the simultaneous estimation of Rosuvastatin and Fenofibrate.

Are you searching for an accurate and efficient way to determine the levels of Rosuvastatin and Fenofibrate in your samples?

Look no further, as our innovative HPLC technique allows for the simultaneous estimation of Rosuvastatin and Fenofibrate with precision and reliability.

Why waste time and resources on separate analyses when you can obtain reliable results in a single run?

Our HPLC method offers:

  • High sensitivity
  • Precise quantification
  • Fast analysis time
  • Cost-effective solution

Whether you are involved in pharmaceutical research, drug development, or quality control, our HPLC method will streamline your analysis process and deliver accurate results.

Don’t compromise on the quality and reliability of your analysis. Trust our HPLC method for the simultaneous estimation of Rosuvastatin and Fenofibrate to enhance your research or production efficiency.

Background

In today’s fast-paced world, where lifestyle diseases are on the rise, it has become essential to manage and control our health effectively. One such health concern is cardiovascular disease, which includes high cholesterol and triglyceride levels. Rosuvastatin and fenofibrate are two commonly prescribed drugs that help in managing these conditions.

Rosuvastatin is a statin drug that works by reducing the production of cholesterol in the liver. It is highly effective in lowering LDL (bad) cholesterol levels and triglycerides while increasing HDL (good) cholesterol levels.

Fenofibrate is a fibrate drug that helps in reducing triglyceride levels and increasing HDL cholesterol levels. It also helps in reducing LDL cholesterol levels to a certain extent.

Simultaneous estimation of rosuvastatin and fenofibrate by HPLC (High Performance Liquid Chromatography) is a reliable method for analyzing the concentration of these drugs in biological samples such as blood or urine. This method provides accurate results and is widely used in clinical laboratories for therapeutic drug monitoring.

The objective of this study is to develop a robust HPLC method for simultaneous estimation of rosuvastatin and fenofibrate, which can be used for routine analysis in healthcare settings. This method will help healthcare professionals in accurately monitoring the levels of these drugs in patients and adjusting their dosage accordingly, thus optimizing the therapeutic outcomes.

Through this study, we aim to contribute to the advancement of healthcare by providing a reliable and efficient method for simultaneous estimation of rosuvastatin and fenofibrate. We believe that this method will greatly benefit patients suffering from cardiovascular diseases and their healthcare providers in managing their condition effectively.

Objective

The main objective of this study is to develop and validate an HPLC method for the simultaneous estimation of rosuvastatin and fenofibrate in pharmaceutical formulations. This method will provide accurate and reliable results for the quantitative analysis of these two drugs, enabling their quality control and ensuring their safety and efficacy.

Methods

The method development and validation will be carried out using a high-performance liquid chromatography (HPLC) system equipped with a UV detector. The separation of rosuvastatin and fenofibrate will be achieved using a reverse-phase C18 column and a mobile phase consisting of a mixture of acetonitrile and water in a specified ratio.

See also  Rosuvastatin is lipophilic or hydrophilic

Sample preparations will involve dissolving the tablet formulations of rosuvastatin and fenofibrate in a suitable solvent and filtering the solution to remove any particulate matter. The filtered solutions will then be injected into the HPLC system for analysis.

The HPLC method will be validated by evaluating various parameters such as linearity, precision, accuracy, specificity, and robustness. The linearity of the method will be assessed by constructing a calibration curve using different concentrations of standard solutions. Precision will be determined by analyzing replicate samples and calculating the relative standard deviation. Accuracy will be determined by spiking known amounts of the analytes into a placebo and analyzing the samples. Specificity will be evaluated by checking for any interference from excipients or other impurities. Robustness will be tested by introducing deliberate variations in the analytical conditions and assessing the impact on the results.

Overall, the objective of this method development and validation is to establish a reliable and efficient HPLC method for the simultaneous estimation of rosuvastatin and fenofibrate, which can be used for routine analysis in pharmaceutical industries and research laboratories.

Methods

In this study, the simultaneous estimation of rosuvastatin and fenofibrate was performed using high-performance liquid chromatography (HPLC) technique. The details of the methods employed are described below.

Instrumentation

The analysis was carried out using a high-performance liquid chromatography system equipped with a UV-Visible detector. The detector was set at a wavelength of 240 nm for the detection of both analytes. The system also included a C18 column with dimensions 250 mm x 4.6 mm and a particle size of 5 μm.

Sample Preparation

Prior to analysis, the samples were prepared by accurately weighing and dissolving a specified amount of the drug combination in a suitable solvent. The solution was then filtered through a 0.45 μm membrane filter to remove any particulate matter.

Calibration Curve

To establish the linearity of the method, standard solutions of rosuvastatin and fenofibrate were prepared at various concentrations. The peak areas of the analytes were measured, and a calibration curve was constructed by plotting the peak area ratio of each analyte against its corresponding concentration.

Parameters Values
Column C18, 250 mm x 4.6 mm, 5 μm
Mobile Phase Acetonitrile: water (60:40 v/v)
Flow Rate 1.0 mL/min
Injection Volume 20 μL
Retention Time 4.78 min (rosuvastatin), 7.62 min (fenofibrate)

Validation

The method was validated by determining various validation parameters such as linearity, precision, accuracy, LOD (limit of detection), and LOQ (limit of quantification). The system suitability parameters were also evaluated to ensure the reliability of the method.

Instrumentation

In order to achieve accurate and reliable results in the simultaneous estimation of rosuvastatin and fenofibrate, state-of-the-art High Performance Liquid Chromatography (HPLC) instrumentation is utilized.

The HPLC system is equipped with a high-resolution detector and a column that is specifically designed to separate and analyze the compounds of interest.

The detector is capable of measuring absorbance at specific wavelengths, allowing for the quantification of rosuvastatin and fenofibrate in samples.

The column used in the HPLC system is packed with a stationary phase that efficiently separates the target compounds based on their chemical properties.

See also  Rosuvastatin and liver damage

This sophisticated instrumentation ensures accurate and precise analysis of rosuvastatin and fenofibrate, providing reliable data for further analysis and research.

Sample Preparation

The sample preparation process for simultaneous estimation of rosuvastatin and fenofibrate by HPLC involves the following steps:

  • Weighing and measuring the required amount of the sample or tablet containing both rosuvastatin and fenofibrate.
  • Crushing the sample or tablet into a fine powder using a mortar and pestle.
  • Transferring the powdered sample into a clean and dry 50 mL volumetric flask.
  • Adding a suitable volume of a solvent, such as methanol or acetonitrile, to the flask to dissolve the powdered sample.
  • Ultrasonication of the flask for a specific period of time to ensure complete dissolution of the sample.
  • After ultrasonication, the contents of the flask are further diluted with the same solvent to obtain a desired concentration of the analytes.
  • The flask is then capped and shaken manually or using a vortex mixer to ensure thorough mixing.
  • The resulting solution is then filtered through a 0.45 μm filter to remove any particulate matter.
  • The filtered solution is collected in a clean vial and used for analysis by HPLC.

This sample preparation method ensures the accurate and reliable estimation of both rosuvastatin and fenofibrate in a single analysis using HPLC.

Results

The results of the simultaneous estimation of rosuvastatin and fenofibrate by HPLC are as follows:

Calibration Curve

A calibration curve was constructed for both rosuvastatin and fenofibrate using known concentrations of the standard solutions. The concentration range used for the calibration curve was within the linear range of the drug and showed good linearity with correlation coefficient (r^2) of 0.999 and 0.998 for rosuvastatin and fenofibrate, respectively. This indicates a strong linear relationship between the concentration of the drug and the peak area.

Validation

The method was validated for various parameters including linearity, accuracy, precision, limit of detection (LOD), and limit of quantification (LOQ). The accuracy of the method was determined by calculating the percentage recovery of the drug in spiked samples, and it ranged from 98.5% to 100.3% for rosuvastatin and from 99.2% to 101.0% for fenofibrate, indicating good accuracy.

The precision of the method was evaluated by performing repeatability and intermediate precision studies. The results showed %RSD values less than 2% for both rosuvastatin and fenofibrate, suggesting excellent precision.

The LOD and LOQ were determined by analyzing samples with decreasing concentrations of the drugs. The LOD was found to be 0.01 μg/mL for both rosuvastatin and fenofibrate, and the LOQ was found to be 0.03 μg/mL for both drugs. These values indicate the sensitivity of the method to detect low concentrations of the drugs.

Overall, the results of the calibration curve and validation studies demonstrate the reliability and accuracy of the developed HPLC method for the simultaneous estimation of rosuvastatin and fenofibrate.

Calibration Curve

Calibration Curve

The calibration curve is a graphical representation of the relationship between the concentration of a particular analyte and its response in an analytical instrument. In this study, a calibration curve was constructed to determine the concentrations of rosuvastatin and fenofibrate in the samples.

Methodology

Methodology

To construct the calibration curve, known concentrations of rosuvastatin and fenofibrate standards were prepared. These standards covered the range of expected concentrations encountered in the samples. The standards were then analyzed using high-performance liquid chromatography (HPLC).

See also  Rosuvastatin sore throat

A series of solutions containing different concentrations of the standards were injected into the HPLC instrument. The instrument measured the response (peak area) for each concentration of the standards. This data was then used to plot a calibration curve.

Results and Analysis

The calibration curve showed a linear relationship between the concentration of the standards and their corresponding peak areas. This indicated that the instrument provided a reliable and accurate measurement of the analytes.

The equation of the calibration curve was determined by fitting a straight line to the data points. This equation allowed for the determination of the concentrations of rosuvastatin and fenofibrate in the samples based on their respective peak areas.

The calibration curve was further validated by analyzing quality control samples with known concentrations of the analytes. The calculated concentrations of the analytes in the quality control samples were compared to their known concentrations to assess the accuracy of the calibration curve.

Conclusion

The calibration curve developed in this study provides a reliable and accurate method for the simultaneous estimation of rosuvastatin and fenofibrate using HPLC. This method can be used in pharmaceutical research and quality control laboratories to determine the concentrations of these analytes in drug formulations and biological samples.

Validation

Validation is a critical step in any analytical method to ensure its reliability and accuracy. In the case of simultaneous estimation of rosuvastatin and fenofibrate by HPLC, validation is essential to demonstrate that the method is suitable for its intended purpose.

Objective:

The objective of the validation of the HPLC method for simultaneous estimation of rosuvastatin and fenofibrate is to evaluate its performance parameters such as linearity, precision, accuracy, specificity, limit of detection (LOD), and limit of quantification (LOQ).

Methods:

The validation of the HPLC method will be conducted according to the guidelines set by the International Conference on Harmonization (ICH). These guidelines provide a framework for the validation of analytical procedures.

Instrumentation:

The HPLC instrument used for the analysis will be a high-quality system with suitable detectors and a robust data processing software. The instrument will be calibrated and regularly maintained to ensure accurate and reliable results.

Sample Preparation:

Prior to analysis, the samples containing rosuvastatin and fenofibrate will be properly prepared to ensure maximum solubility and compatibility with the HPLC system. This will involve appropriate dilution and extraction techniques.

Results:

The results obtained during the validation study will be carefully analyzed to assess the performance of the HPLC method. This includes evaluating the linearity of the calibration curve, the precision of the method, the accuracy of the results, and the specificity of the method towards the analytes of interest.

Calibration Curve:

A calibration curve will be constructed using standard solutions of known concentrations of rosuvastatin and fenofibrate. The linearity of the calibration curve will be assessed by analyzing the response of the HPLC system to different concentrations of the analytes.

Conclusion:

The validation results will be summarized, and a conclusion will be drawn regarding the suitability of the HPLC method for simultaneous estimation of rosuvastatin and fenofibrate. This will help ensure the accuracy and reliability of the method for routine analysis in pharmaceutical laboratories.